Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02986984 · ClinicalTrials.gov registry record
Transformative Research in Diabetic Nephropathy
A clinical trial of Diabetic Nephropathies and Diabetic Glomerulosclerosis, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 400
- Enrollment target
- 17
- Study locations
NCT02986984 is a study of Diabetic Nephropathies and Diabetic Glomerulosclerosis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 400 participants, above the 94-participant average among 12 other Diabetic Nephropathies trials with a reported enrollment target (326% higher). The trial reports 17 study locations across 13 states.
The verdict
NCT02986984, a study of Diabetic Nephropathies and Diabetic Glomerulosclerosis, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (\> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of observation. High through-put genomic analysis associated with genetic and biomarker testing will serve to identify key potential therapeutic targets for DKD by comparing patients with rapid and slow progression patterns. Each participating clinical site will search for, consent, harvest the biopsy sample, and enroll the participants as required for the TRIDENT protocol.
Conditions Studied
Interventions
- OTHER There is no intervention
Study Locations (17)
New York
- Mount Sinai Hospital - New York
- Columbia University - New York
- Albert Einstein College of Medicine - The Bronx
California
- University of Southern California - Los Angeles
- Stanford University - Palo Alto
Pennsylvania
- Lehigh Valley Health Network - Allentown
- University of Pennsylvania - Philadelphia
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Yale University - New Haven
Illinois
- Northwestern University - Chicago
Michigan
- University of Michigan - Ann Arbor
New Mexico
- University of New Mexico - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2016-12 |
| Est. Completion | 2027-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02986984
The ClinicalTrials.gov registry entry for NCT02986984 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 94-participant average among 12 other Diabetic Nephropathies trials with a reported enrollment target (326% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Nephropathies appearing as the primary indexed condition, and to 1 intervention - of which There is no intervention is the first listed.
NCT02986984 reports 17 study locations spanning 13 distinct geographic areas - top geographies include New York, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02986984 about?
NCT02986984 is a clinical study titled "Transformative Research in Diabetic Nephropathy". This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and...
What is the current status of trial NCT02986984?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2016-12. Estimated completion is 2027-06.
What conditions does trial NCT02986984 study?
This clinical trial studies the following conditions: Diabetic Nephropathies, Diabetic Glomerulosclerosis.
What interventions are being tested in trial NCT02986984?
The interventions under investigation include: There is no intervention (OTHER).
Who is sponsoring clinical trial NCT02986984?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02986984 being conducted?
This trial has 17 study locations across Arkansas, California, Connecticut, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Nephropathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Formoterol in Diabetes
RECRUITING · Phase 2
-
Study of WAL0921 in Patients With Glomerular Kidney Diseases
RECRUITING · Phase 2
-
Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)
RECRUITING
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RECRUITING · Phase 3
-
Transformative Research in Diabetic Nephropathy 2.0
RECRUITING
-
MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.